|
End-of-day quote
Nasdaq
2026-10-20
|
5-day change | 1st Jan Change | ||
| 1.670 USD | +5.70% |
|
0.00% | -81.51% |
| 10-15 | EnGene Therapeutics Inc. - Special Call | |
| 09-20 | EnGene Therapeutics Inc.(NasdaqCM:ENGN) dropped from S&P Global BMI Index | CI |
Company Valuation: enGene Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: October | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | - | 451.1 | 369.1 | 104.5 | - | - |
| Change | - | - | -18.18% | -71.68% | - | - |
| Enterprise Value (EV) 1 | - | 236 | 190.7 | -79.98 | 30.08 | -36.08 |
| Change | - | - | -19.19% | -141.94% | 137.61% | -219.93% |
| P/E | -0.14x | -6.06x | -3.15x | -0.85x | -1.03x | -1.53x |
| PBR | - | 1.65x | 2.2x | 0.57x | 1.42x | 1.01x |
| PEG | - | 0.1x | -0.1x | 0x | 0.1x | 0x |
| Capitalization / Revenue | - | - | - | - | 18.7x | 2.79x |
| EV / Revenue | - | - | - | - | 5.38x | -0.96x |
| EV / EBITDA | - | -3.81x | -1.55x | 0.67x | -0.28x | 0.29x |
| EV / EBIT | - | -3.79x | -1.55x | 0.63x | -0.27x | 0.36x |
| EV / FCF | - | - | -1.89x | 0.58x | -0.2x | 0.25x |
| FCF Yield | - | - | -52.8% | 173% | -501% | 403% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -151.2 | -1.46 | -2.29 | -1.831 | -1.515 | -1.021 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 5.597 | 37.48 |
| EBITDA 1 | - | -61.97 | -122.7 | -119.4 | -107.9 | -125.7 |
| EBIT 1 | - | -62.3 | -123.2 | -127.1 | -112.9 | -100.7 |
| Net income 1 | -99.92 | -55.14 | -117.3 | -124.5 | -112.5 | -104.3 |
| Net Debt 1 | - | -215.2 | -178.4 | -184.5 | -74.46 | -140.6 |
| Reference price 2 | 21.695 | 8.850 | 7.210 | 1.560 | 1.560 | 1.560 |
| Nbr of stocks (in thousands) | - | 50,974 | 51,192 | 67,016 | - | - |
| Announcement Date | 1/29/24 | 12/19/24 | 12/22/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.85x | - | 0.67x | -.--% | 105M | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 7.93x | 26.43x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| Average | 24.01x | 26.45x | 14.20x | 0.29% | 38.32B | |
| Weighted average by Cap. | 26.71x | 25.32x | 15.93x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ENGN Stock
- Valuation enGene Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
